Kiniksa officer Mark Ragosa proposes $3.39M share sale

The listed sale route is through Charles Schwab & Co., Inc. on NASDAQ, with the shares tied to a cashless option exercise.

Available on EDGAR 11/02/2026 - 05:14 PM EST Accepted by SEC EDGAR 11/02/2026 - 05:13 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) officer Mark Ragosa reported a proposed sale of 36,783 Class A ordinary shares, with an aggregate market value of $3,390,075.00. The notice lists November 2, 2026 as the approximate sale date, Charles Schwab & Co., Inc. as broker, and NASDAQ as the market. The acquisition entry names Kiniksa Pharmaceuticals, Ltd. and describes an employee stock option exercise with broker payment for a cashless exercise.

Key Figures

Proposed sale: 36,783 shares Aggregate market value: $3,390,075.00 Class A ordinary shares outstanding: 48,836,965 shares

3 metrics

Proposed sale 36,783 shares Class A ordinary shares; approximate sale date November 2, 2026

Aggregate market value $3,390,075.00 Securities listed for the proposed sale

Class A ordinary shares outstanding 48,836,965 shares Number listed in the securities information

Key Terms

Rule 144, Employee Stock Option Exercise, Cashless Exercise

3 terms

Rule 144 regulatory

"paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Employee Stock Option Exercise financial

"Employee Stock Option Exercise"

Cashless Exercise financial

"Broker Payment for Cashless Exercise"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KNSA shares does Mark Ragosa propose to sell?

Mark Ragosa, identified as an officer, reported a proposed sale of 36,783 Class A ordinary shares, with an aggregate market value of $3,390,075.00. The notice lists November 2, 2026 as the approximate sale date, Charles Schwab & Co., Inc. as broker, and NASDAQ as the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001835458
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kiniksa Pharmaceuticals International, plc
SEC File Number	001-38492
Address of Issuer	105 PICCADILLY, SECOND FLOOR LONDON UNITED KINGDOM W1J 7NJ
Phone	7814319100
Name of Person for Whose Account the Securities are To Be Sold	Ragosa Mark
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	36783	3390075.00	48836965	11/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A ordinary shares	11/02/2026	Employee Stock Option Exercise	Kiniksa Pharmaceuticals, Ltd.			36783	11/02/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	07/29/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Mark Ragosa
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)